Roche sizes up first BTK inhibitor approval on Phase III MS victory
Roche is eyeing regulatory approval for its oral multiple sclerosis (MS) hopeful, fenebrutinib, after the drug met its primary endpoints …
Post
-
-
Sharp Services invests $100 million in US and European facilities to increase capacity and service offerings
Sharp Services, a leader in pharmaceutical packaging, clinical trial services and sterile manufacturing has announced a $100 million investment across its …
-
AHA 2025: SHR-1918’s impact on hyperlipidaemia through angiopoietin-like 3 inhibition
On 10 October, at the American Heart Association (AHA) 2025 conference in New Orleans, Louisiana, US, during a late-breaking session …
-
enGene’s NMIBC gene therapy touts 63% complete response in pivotal trial
enGene’s gene therapy for high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) has touted a 63% complete response (CR) …
-
Physical activity effects mortality risk in epilepsy
Exercise has traditionally been associated with better health outcomes. According to the World Health Organization, there are various physical and …
-
Simcere’s SIM0278 enters Phase II trial in China for atopic dermatitis
Simcere Pharmaceutical’s IL-2 mutant fusion protein (IL-2 mu-Fc), SIM0278, has entered a Phase II trial in China, for moderate-to-severe atopic …
-
Cogent’s stock soars on Phase III gastrointestinal cancer data
Cogent Biosciences' stock has soared after its lead asset, bezuclastinib plus sunitinib, outperformed sunitinib alone in a pivotal gastrointestinal cancer …
-
Neurocrine’s depression treatment misses main goal in Phase II study
Neurocrine Biosciences has reported that its Phase II trial assessing NBI-1070770 in the adult population with major depressive disorder (MDD) …
-
AHA 2025: sotatercept shows survival edge in pulmonary arterial hypertension
At the 2025 American Heart Association (AHA) Scientific Sessions in New Orleans, researchers shared pooled results from three major clinical …
-
AHA 2025: satralizumab shows benefit in immune-driven pulmonary arterial hypertension
At the 2025 American Heart Association (AHA) Scientific Sessions in New Orleans, investigators from Japan presented results from the SATISFY-JP …
-
Muna doses first subjects in study of MNA-001 to treat early Alzheimer’s
Muna Therapeutics has dosed the first participants in a Phase I trial of its lead asset MNA-001 to treat early …
-
Sotagliflozin demonstrates structural and functional benefits in nondiabetic HFpEF
On 8 November at this year’s American Heart Association conference, during a clinical session on the topic of 'Heart Failure …
-
Aulos looks to Phase III for IL-2 mAb in NSCLC and melanoma
Aulos Bioscience’s cancer therapy, imneskibart, could enter a registrational study either in melanoma, non-small cell lung cancer (NSCLC) or both, …
-
Dupixent set for ninth US approval after Phase III AFRS success
Sanofi and Regeneron’s Dupixent (dupilumab) could be set for its ninth US approval after the drug met all the primary …
-
Forced degradation studies: A critical lens into pharmaceutical stability
Forced degradation studies simulate harsh conditions to accelerate degradation, helping us uncover potential vulnerabilities in a molecule’s structure and predict …
